Novogene(SH:688315) Sou Hu Cai Jing·2025-08-20 11:34Core Insights - The company, Beijing Novogene Co., Ltd., closed at 16.03 yuan on August 20, with a decline of 1.54%, resulting in a rolling PE ratio of 33.77 times and a total market capitalization of 6.672 billion yuan [1] - In the medical services industry, the average PE ratio is 49.21 times, with a median of 65.65 times, placing Novogene at the 20th position in the industry ranking [1] - As of the 2025 semi-annual report, 12 institutions held shares in Novogene, with a total of 88.8692 million shares valued at 1.255 billion yuan [1] Company Overview - Novogene specializes in providing multi-level research technology services and solutions for life sciences, medical, and clinical application research, along with developing innovative gene testing medical devices [1] - The main products include life science basic research services, medical research and technology services, library sequencing platform services, and others [1] - As of June 30, 2025, Novogene has published or been cited in over 34,574 SCI articles, with a cumulative impact factor of 227,372.12, and holds 82 invention patents and 547 software copyrights [1] Financial Performance - For the first half of 2025, the company reported a revenue of 1.04 billion yuan, representing a year-on-year increase of 4.36%, and a net profit of 78.7296 million yuan, with a year-on-year growth of 1.03% [1] - The sales gross margin stood at 40.80% [1]